A W Schmidt

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile
    A W Schmidt
    CNS Discovery, Groton Laboratories, Pfizer Global Research and Development, MS 8220 4155, 558 Eastern Point Road, Groton, CT 06340 1596, USA
    Eur J Pharmacol 425:197-201. 2001
  2. ncbi request reprint Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation
    H Rollema
    Pfizer Inc, Department of Neuroscience, Groton, CT 06340, USA
    Eur J Pharmacol 338:R3-5. 1997
  3. doi request reprint Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors
    S Grimwood
    Neuroscience Research Unit, Pfizer Inc, Groton, CT 06340, USA
    J Pharmacol Exp Ther 339:555-66. 2011
  4. ncbi request reprint Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain
    D E Johnson
    Department of Neuroscience, Pfizer Global Research and Development, MS 8220-4159, Groton, CT 06340, USA
    Eur J Pharmacol 425:203-10. 2001

Collaborators

Detail Information

Publications4

  1. ncbi request reprint Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile
    A W Schmidt
    CNS Discovery, Groton Laboratories, Pfizer Global Research and Development, MS 8220 4155, 558 Eastern Point Road, Groton, CT 06340 1596, USA
    Eur J Pharmacol 425:197-201. 2001
    ....
  2. ncbi request reprint Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation
    H Rollema
    Pfizer Inc, Department of Neuroscience, Groton, CT 06340, USA
    Eur J Pharmacol 338:R3-5. 1997
    ..Agonist affinity for 5-HT1A receptors could thus be a desirable feature in the design of new antipsychotics...
  3. doi request reprint Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors
    S Grimwood
    Neuroscience Research Unit, Pfizer Inc, Groton, CT 06340, USA
    J Pharmacol Exp Ther 339:555-66. 2011
    ..1 mg/kg, which aligned well with the ED(50) values obtained from the rat in vivo binding and efficacy assays. These data provide further evidence that KOR antagonists have potential for the treatment of depression and addiction disorders...
  4. ncbi request reprint Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain
    D E Johnson
    Department of Neuroscience, Pfizer Global Research and Development, MS 8220-4159, Groton, CT 06340, USA
    Eur J Pharmacol 425:203-10. 2001
    ....